Results from the phase III SPOTLIGHT trial show that the investigational mAb zolbetuximab plus chemotherapy improves progression-free survival and overall survival in patients newly diagnosed with claudin 18.2–positive, HER2-negative locally advanced inoperable or metastatic gastric or gastroesophageal junction cancer. The drug could become a standard treatment option for these patients.

You do not currently have access to this content.